Tezepelumab
Other Systemic Drugs For Obstructive Airway Diseases
Sold as Tezspire
- Drug class
- Other Systemic Drugs For Obstructive Airway Diseases
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 5
Overview
Tezepelumab is an active pharmaceutical ingredient in the Other Systemic Drugs For Obstructive Airway Diseases group (R03DX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 1, 2026 |
| EU European Union | EMA | 1 | October 22, 2025 |
| CA Canada | Health Canada | 2 | March 5, 2026 |
GBUnited Kingdom· MHRA
2 products
Uses
Asthma Tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Chronic rhinosinusitis with nasal polyps (CRSwNP) Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control.
How to take
EUEuropean Union· EMA
1 product
Uses
Asthma Tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Chronic rhinosinusitis with nasal polyps (CRSwNP) Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control.
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PLGB179010372 · revised May 1, 2026
- [2]European Medicines Agency · EMEA/H/C/005588 · revised October 22, 2025
- [3]Health Canada (DPD) · 02529548 · revised March 5, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.